KraneShares Public Private AI and Technology ETF (AGIX)

KraneShares AI ETF AGIX Buys Shares of Private Autonomous Driving Tech Provider Nuro

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- KraneShares today announced that its KraneShares Artificial...

KraneShares Hosts Technology Investor Day and KIQQ Opening Bell at Nasdaq, Showcasing AI, Humanoid Robotics, and Risk-Managed Exposure Across AGIX, KOID, and KIQQ

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- KraneShares, a specialist investment manager focused on global...

KraneShares AI ETF AGIX Now Owns SpaceX Shares Post-xAI Merger

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- KraneShares, a leading provider of exchange-traded funds (ETFs...

KraneShares’ Public-Private Fund AGIX Increases Ownership in Elon Musk-backed xAI

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- KraneShares, a leading provider of thematic exchange-traded...

KraneShares Artificial Intelligence & Technology ETF (AGIX) Joins LPL Financial’s No-Transaction-Fee Platform

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- KraneShares, a leading provider of exchange-traded funds (ETFs...

KraneShares AI ETF AGIX Buys Anthropic Shares

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- KraneShares today announced its KraneShares Artificial...

- Current report filing (8-K)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________ FORM 8-K...

- Withdrawal of Registration Statement (RW)

      [AtheroGenics Letterhead] October 10, 2008 VIA FACSIMILE AND EDGAR Securities and Exchange Commission...

Atherogenics Inc - Current report filing (8-K)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________ FORM 8-K...

Atherogenics Inc - Current report filing (8-K)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________ FORM 8-K...

Atherogenics Inc - Current report filing (8-K)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________ FORM 8-K...

Atherogenics Inc - Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO...

Atherogenics Inc - Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO...

Atherogenics Inc - Current report filing (8-K)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________ FORM 8-K...

Atherogenics Inc - Confidential Treatment Order (CT ORDER)